GenSight Biologics presents its financial situation and therapeutic advances

On July 8, 2026, GenSight Biologics reported cash on hand of €1.7 million as of June 30, 2026, a decrease from €3.2 million as of March 31, 2026. This reduction is due to expenses related to early access programs for GS010/LUMEVOQ® and preparations for the Phase III RECOVER trial. In the first half of 2026, the company raised €6.8 million through its early access programs, including €4.3 million in the second quarter.

The company is continuing to optimize the GS010 manufacturing process at Catalent. It has more than 60 vials available to treat patients until the first half of 2027. However, 2026 revenues will not cover the costs of the Phase III RECOVER trial. GenSight plans to expand its clinical teams during the second half of 2026. The half-year results will be published on September 29, 2026.